CAS 131438-79-4|Beta-Amyloid(1-40)
| Common Name | Beta-Amyloid(1-40) | ||
|---|---|---|---|
| CAS Number | 131438-79-4 | Molecular Weight | 4329.867 |
| Density | / | Boiling Point | / |
| Molecular Formula | C194H295N53O58S | Melting Point | / |
| MSDS | USA | Flash Point | / |
Names
| Name | amyloid beta-protein (human, 1-40) trifluoroacetate |
|---|---|
| Synonym | More Synonyms |
Beta-Amyloid(1-40) BiologicalActivity
| Description | β-Amyloid (1-40) is a primary protein in plaques found in the brains of patients with Alzheimer's disease. |
|---|---|
| Related Catalog | Signaling Pathways >>Epigenetics >>PKCSignaling Pathways >>TGF-beta/Smad >>PKCNatural Products >>OthersResearch Areas >>Neurological DiseasePeptides |
| In Vitro | β-Amyloid (1-40) and (1-42) are major components of senile plaque amyloids, are physiological peptides present in the brain, cerebrospinal fluid (CSF) and plasma. The levels of CSF β-Amyloid (1-40) and (1-42) show a U-shaped natural course in normal aging[1].Chronic infusion of beta-amyloid (1-40) for 14 days into the rat cerebroventricle decreased the activity of soluble protein kinase C (PKC) in the hippocampus. Subcellular translocation of PKC to membrane fraction in hippocampal slices of rats treated with beta-amyloid (1-40) is completely abolished under acute stimulation with 0.5 microM phorbol-dibutyrate (PDBu)[2]. |
| In Vivo | Chronic infusion of β-Amyloid (1-40) into rat cerebroventricle leads to deficit in spatial and non-spatial memory formation[2]. Chronic treatment of β-Amyloid (1-40) does not change lever-pressing performance significantly, but performance declined significantly 30 days after termination of the chronic daily regimen. The soluble unaggregated form of β-Amyloid (1-40), injected into the dorsal hippocampus, does not appear to have behavioral effects on performance or short-term working memory in rats, but multiple repeat injections produced performance decrements several weeks later. Repeated injection of β-Amyloid (1-40) through indwelling cannulae shows promise for development of an animal model of Alzheimer's disease[3]. |
| Animal Admin | Rats: HPLC buffer insures the β-Amyloid (1-40) does not aggregate in solution prior to injection, β-Amyloid (1-40) and vehicle are bilaterally infused into the hippocampus, 20 min before experimental sessions, in volumes of 1, 2 and 3 μL per side, at a rate of <1 μL/min. Different volumes of the 1 μM solution are used. Volumes (doses) are given in random order and at least three sham-injection sessions are interposed between β-Amyloid (1-40) or vehicle injections. All rats receive all doses of β-Amyloid (1-40) under the acute injection regimen[3]. |
| References | [1]. Shoji M, et al. Cerebrospinal fluid Abeta40 and Abeta42: natural course and clinical usefulness. Front Biosci. 2002 Apr 1;7:d997-1006. [2]. Cleary J, et al. Beta-amyloid(1-40) effects on behavior and memory. Brain Res. 1995 Jun 5;682(1-2):69-74. [3]. Olariu A, et al. Memory impairment induced by chronic intracerebroventricular infusion of beta-amyloid (1-40) involves downregulation of protein kinase C. Brain Res. 2002 Dec 13;957(2):278-86. |
Chemical & Physical Properties
| Molecular Formula | C194H295N53O58S |
|---|---|
| Molecular Weight | 4329.867 |
| Exact Mass | 4329.155 |
| Appearance of Characters | powder | white |
| InChIKey | FEWOUVRMGWFWIH-UHFFFAOYSA-N |
| SMILES | CCC(C)C(NC(=O)C(C)NC(=O)CNC(=O)C(CCCCN)NC(=O)C(CC(N)=O)NC(=O)C(CO)NC(=O)CNC(=O)C(NC(=O)C(CC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(Cc1ccccc1)NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCCN)NC(=O)C(CCC(N)=O)NC(=O)C(Cc1c[nH]cn1)NC(=O)C(Cc1c[nH]cn1)NC(=O)C(NC(=O)C(CCC(=O)O)NC(=O)C(Cc1ccc(O)cc1)NC(=O)CNC(=O)C(CO)NC(=O)C(CC(=O)O)NC(=O)C(Cc1c[nH]cn1)NC(=O)C(CCCNC(=N)N)NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(N)CC(=O)O)C(C)C)C(C)C)C(C)C)C(=O)NC(C(=O)NCC(=O)NC(CC(C)C)C(=O)NC(CCSC)C(=O)NC(C(=O)NCC(=O)NCC(=O)NC(C(=O)NC(C(=O)O)C(C)C)C(C)C)C(C)C)C(C)CC |
| Storage condition | −20°C |
| Water Solubility | H2O: ~6 mg/mL |
Safety Information
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
Articles9
More Articles| Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 250 , 279, (1990) The amyloid beta protein is deposited in the brains of patients with Alzheimer's disease but its pathogenic role is unknown. In culture, the amyloid beta protein was neurotrophic to undifferentiated h... | |
| Astrocytes containing amyloid beta-protein (Abeta)-positive granules are associated with Abeta40-positive diffuse plaques in the aged human brain. Am. J. Pathol. 152 , 983-992, (1998) Amyloid beta-protein (Abeta) is the major component of senile plaques that emerge in the cortex during aging and appear most abundantly in Alzheimer's disease. In the course of our immunocytochemical ... | |
| Aggregation state and neurotoxic properties of Alzheimer beta-amyloid peptide. Neurodegeneration 4 , 23-32, (1995) The behaviour of synthetic batches of beta-amyloid (beta A) 1-40 peptide in solution has been studied. The effects of beta A1-40 on a PC12 cell toxicity assay was dependent upon the time of preincubat... |
Synonyms
| beta Amyloid (1-40) human |
| β-amyloid 40 |
| Amyloid β-Peptide (1-40) (human) |
| Amyloidb-Peptide(1-40)(human) |
| amyloid β protein fragment 1-40 |
| Abeta(1-40) |
| β-amyloid protein 40 |
| M.W. 4329.86 C194H295N53O58S |
| AMYLOID B-PROTEIN FRAGMENT 1-40 |
| SS-AMYLOID (1-40), RAT |
| aβ40 |
| H-Asp-Ala-Glu-Phe-Gly-His-Asp-Ser-Gly-Phe-Glu-Val-Arg-His-Asp-Ser-Gly-Phe-Glu-Val-Arg-His-Gln-Lys-Leu-Val-Gly-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-OH |
| Abeta40 |
| Human β-amyloid peptide (1-40) |
| β-Amyloid (1-40) |
